Spectranetics Delivers on Laser's Promise
Executive SummaryAfter a bright promise in the early 1980s, cardiac lasers fell out of favor due to high complication rates and equivocal clinical results. Laser pioneer Spectranetics faced those problems and more, causing the company to languish in the 1990s. Now its back, with a new marketing partner, US Surgical, in a hot new area, TMR, and a strategy that allows the company to spread its risk.
You may also be interested in...
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.